ASCINA BLOG

Development and applications of a SARS-CoV-2 antibody test.

By Monika Trebo | July 6, 2020

Short Description:

Dr. Stadlbauer will describe his role in developing a serological enzyme-linked immunosorbent assay (ELISA) for the screening and identification of human SARS-CoV-2 seroconverters. This assay does not require the handling of infectious virus, can be adjusted to detect different antibody types in serum and plasma and is amenable to scaling. Serological assays are of critical importance to help define previous exposure to SARS-CoV-2 in populations, identify highly reactive human donors for convalescent plasma therapy and investigate correlates of protection.

Daniel Stadlbauer, PhD

Daniel received both his Master’s Degree and Doctoral Degree from the University of Natural Resources and Life Sciences, Vienna. Daniel undertook his doctoral studies as a visiting student in the Krammer Laboratory and was interested in investigating countermeasures against emerging avian influenza subtype H7N9 viruses, allowing him to gain insights into H7N9 vaccine design.

In 2019, Daniel joined the Krammer Laboratory as a postdoctoral fellow. His current research interests include investigating the influenza virus neuraminidase as a vaccine antigen, characterizing anti-neuraminidase antibodies, and aiding in the development of a universal influenza vaccine candidate. Additionally, Daniel is overseeing and managing the influenza serology core in the Krammer Laboratory. Daniel published more than 18 peer-reviewed publications in high impact journals, including key-publications around COVID-19 testing. Find him on Twitter @DanielStadlb.

Date and Time:

July 16, 2020, 12:00 PM Eastern Time (US and Canada)

Please RSVP by July 15 to events@ascina.at

Flyer - ASciNA Virtual Talk Daniel Stadlbauer

Categories: ASciNA Virtual Talk     |    
    |     0 Comments